首页> 外文期刊>Frontiers in Oncology >Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study
【24h】

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study

机译:酪氨酸激酶抑制剂抗性增加了非小细胞肺癌脑转移脑转移后脑放射坏死的风险:多制度回顾性案例控制研究

获取原文
           

摘要

Objective: This study aimed to investigate the relationship between the timing of stereotactic radiosurgery (SRS) intervention and the complications of cerebral radiation necrosis (CRN) in patients with brain metastases of lung adenocarcinoma who received tyrosine kinase inhibitor (TKI) treatment. Methods: A total of 361 targets from 257 patients with brain oligometastases of lung adenocarcinoma who received CyberKnife treatment between 2010 and 2017 were retrospectively collected from three CyberKnife centers. The difference in brain necrosis between patients with or without TKI application was statistically counted. Logistic regression analysis was used to analyze the effect of applying TKI on the occurrence of CRN in patients and the effect of SRS before and after TKI resistance on CRN. Results: The rate of CRN in the TKI group was significantly higher than that in the non-TKI group. The incidence of brain necrosis in patients undergoing SRS after drug resistance was significantly higher than that in patients undergoing SRS before drug resistance. Regression analysis showed that combination of TKI with SRS, and SRS after TKI resistance were important influencing factors for CRN. Conclusion: Performing the SRS for brain metastases after TKI resistance worsened the occurrence of CRN of patients treated with TKI. Clinical Trial Registration: Chinese clinical trial registry, http://www.chictr.org.cn/edit.aspx?pid=38395&htm=4 , Registration number: ChiCTR1900022750.
机译:目的:本研究旨在探讨肺腺癌抑制剂(TKI)治疗肺腺癌脑转移患者脑转移患者脑转移患者脑部辐射坏死(CRN)之间的关系。方法:从三个Cyber​​ Knife中心回顾性地收集了来自2010年和2017年间肺腺癌肺腺癌患者的257例脑脱粒蛋白患者的361名靶标。有或没有TKI申请的患者之间的脑坏死差异在统计上统计学。物流回归分析用于分析TKI对患者CRN发生的影响及其在CRN上的TKI电阻前后SRS的效果。结果:TKI集团C​​RN率明显高于非TKI集团。在耐药性耐药后进行SRS患者的脑坏死的发病率显着高于耐药前SRS患者。回归分析表明,TKI与SRS的组合,TKI抗性后的SRS是CRN的重要影响因素。结论:在TKI抗性后对脑转移进行SRS造成TKI治疗的患者CRN的发生。临床试验注册:中国临床试验登记处,http://www.chictr.org.cn/edit.aspx?pid=38395&htm=4,注册号:chictr1900022750。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号